Ready Capital Corporation 5.75% RCC
25.04 USD 0.00 (+0.00%)
At closeFeb 13, 2026, 4:00 PM EST
25.04 0.00 0.00%
After hours · Feb 13, 4:00 PM ET
25.04 Day range 25.06
52-week range unavailable
- YTD
- -0.04%
- 1 year
- +2.20%
News
newsfilecorp.com Sranan Gold Corp. Announces Engagement of Research Capital Vancouver, British Columbia--(Newsfile Corp. - November 4, 2026) - Sranan Gold Corp. (CSE: SRAN) (OTCQB: SRANF) (FSE: P84) (Tradegate: P84) ("Sranan" or the "Company") announces that it has entered…
gurufocus.com Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, tod
gurufocus.com Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free surv
marketbeat.com Arcus Biosciences Sees $5B-$10B RCC Opportunity for Casdatifan at Investor Day Arcus Biosciences NYSE: RCUS presented updated clinical and translational data for casdatifan, its investigational HIF-2 alpha inhibitor, outlining development plans across first-line, second-line…
gurufocus.com Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC) Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Hu
marketbeat.com Kura Oncology Reports 50% Response Rate in RCC Combination Study Kura Oncology NASDAQ: KURA presented updated results from its Phase 1 FIT-001 trial evaluating darlifarnib in combination with cabozantinib for locally advanced or metastatic renal cell carcinoma…
etftrends.com Bitcoin Meets Sustainability: 7RCC Launches Crypto & Carbon Credit ETF Digital assets and environmental sustainability have long been viewed as opposing forces. However, a new bitcoin ETF aims to bridge that gap by investing in carbon credit futures to offset the…
businesswire.com 7RCC Spot Bitcoin and Carbon Credit Futures ETF (NYSE Arca: BTCK) Begins Trading MIAMI--(BUSINESS WIRE)--7RCC Global, a financial technology and research firm focused on bridging traditional capital markets, digital assets, and regulated market infrastructure, today marked the…
gurufocus.com Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 [url="]Exelixis, Inc.[/url] (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYXÂ
gurufocus.com FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibi
gurufocus.com Comstock Announces Summerbration 2026 at Reston Station [url="]Comstock Holding Companies, Inc.[/url] (Nasdaq: CHCI) ("Comstock"), a leading asset manager, developer, and operator of mixed-use and transit-oriented p
businesswire.com Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC) RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With…
businesswire.com KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC) RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEY + WEL as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death Compared to KEYTRUDA Mono in Certain Patients With Earlier-Stage RCC.
businesswire.com WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG Plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated RCC…
seekingalpha.com Ready Capital Corporation (RC) Q2 2025 Earnings Call Transcript Ready Capital Corporation (RC) Q2 2025 Earnings Call Transcript
seekingalpha.com Ready Capital: Value Destruction Proceeds On Schedule Ready Capital continues to face severe challenges. The leverage and rising delinquencies have already destroyed tons of tangible equity. RC remains suitable only for traders seeking short-term…
seekingalpha.com Ready Capital Corporation (RC) Q3 2025 Earnings Call Transcript Ready Capital Corporation ( RC ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Andrew Ahlborn - CFO & Secretary Thomas Capasse - Chairman, CEO & Chief Investment Officer…
seekingalpha.com I Came In Like A Ready Capital! Ready Capital reported another poor quarter with negative distributable earnings. Loans that are more than 60 days delinquent rose once again. The company borrowed more funds to buyback shares.
seekingalpha.com Ready Capital Corporation (RC) Q3 2025 Earnings Call Transcript Ready Capital Corporation (NYSE:RC ) Q3 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Adam Zausmer - Chief Credit Officer Andrew Ahlborn - CFO & Secretary Thomas Edward…
seekingalpha.com Attractive Short-Dated Bond, 8.5% YTM, From Ready Capital RCC is a short-term, exchange-listed baby bond from Ready Capital, maturing in February 2026, offering an 8.5% yield to maturity. The bond's very short duration minimizes market risk, making solvency…
benzinga.com Another Setback for Sutent - Analyst Blog